ArticleMethods in molecular biology (Clifton, N.J.)2017
Exploring Protein-Protein Interactions as Drug Targets for Anti-cancer Therapy with In Silico Workflows.
Article in Methods in molecular biology (Clifton, N.J.), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- Eugenol-Derived Piperazine Mannich Bases as Selective Inhibitors of Mayaro Virus: In Vitro Antiviral Evaluation and Mechanistic Insights.Journal of medical virology · 2026Article
- Enhancing mutation impact prediction in protein-protein interactions through interpretable graph-based multi-level feature interactions.Bioinformatics (Oxford, England) · 2026Article
- Screening Enamine Fragments Library in the Quest for Novel SOS2 Inhibitors: Pharmacophore Modelling, Molecular Docking, MMGBSA Calculations, and MD Simulation.Journal of pharmacy & bioallied sciences · 2025Article
- Systematic investigation of machine learning on limited data: A study on predicting protein-protein binding strength.Computational and structural biotechnology journal · 2024Article
- DiPPI: A Curated Data Set for Drug-like Molecules in Protein-Protein Interfaces.Journal of chemical information and modeling · 2024Article
- Drug discovery by targeting the protein-protein interactions involved in autophagy.Acta pharmaceutica Sinica. B · 2023Review
- Gibbs Energy and Gene Expression Combined as a New Technique for Selecting Drug Targets for Inhibiting Specific Protein-Protein Interactions.International journal of molecular sciences · 2023Article
- Determining human-coronavirus protein-protein interaction using machine intelligence.Medicine in novel technology and devices · 2023Article
- Identification of hub genes involved in cisplatin resistance in head and neck cancer.Journal, genetic engineering & biotechnology · 2023Article
- AlphaFold, Artificial Intelligence (AI), and Allostery.The journal of physical chemistry. B · 2022Review
- Identification of Putative Vaccine and Drug Targets against the Methicillin-ResistantMolecules (Basel, Switzerland) · 2022Article
- GraphDTI: A robust deep learning predictor of drug-target interactions from multiple heterogeneous data.Journal of cheminformatics · 2021Article
- A Novel Protein Mapping Method for Predicting the Protein Interactions in COVID-19 Disease by Deep Learning.Interdisciplinary sciences, computational life sciences · 2021Article
- NMR as a "Gold Standard" Method in Drug Design and Discovery.Molecules (Basel, Switzerland) · 2020Review
- Mutation effect estimation on protein-protein interactions using deep contextualized representation learning.NAR genomics and bioinformatics · 2020Article
- MutaBind2: Predicting the Impacts of Single and Multiple Mutations on Protein-Protein Interactions.iScience · 2020Article
- Application of Fragment-Based Drug Discovery to Versatile Targets.Frontiers in molecular biosciences · 2020Review
- The Molecular Basis of JAZ-MYC Coupling, a Protein-Protein Interface Essential for Plant Response to Stressors.Frontiers in plant science · 2020Article
- A systems biology approach towards the identification of candidate therapeutic genes and potential biomarkers for Parkinson's disease.PloS one · 2019Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
We describe a computational protocol to aid the design of small molecule and peptide drugs that target protein-protein interactions, particularly for anti-cancer therapy. To achieve this goal, we explore multiple strategies, including finding binding hot spots, incorporating chemical similarity and bioactivity data, and sampling similar binding sites from homologous protein complexes. We demonstrate how to combine existing interdisciplinary resources with examples of semi-automated workflows. Finally, we discuss several major problems, including the occurrence of drug-resistant mutations, drug promiscuity, and the design of dual-effect inhibitors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.